RSVPreF3

GSK hits back in high-stakes RSV vaccine game, posting phase 3 data that suggest it has edge on Pfizer
Fierce Biotech
Thu, 10/13/22 - 09:47 am
GSK
RSV
vaccines
clinical trials
Pfizer
JNJ
Moderna Therapeutics
RSVPreF3